Perrigo Company PLC banner

Perrigo Company PLC
NYSE:PRGO

Watchlist Manager
Perrigo Company PLC Logo
Perrigo Company PLC
NYSE:PRGO
Watchlist
Price: 11.69 USD -1.1% Market Closed
Market Cap: $1.6B

P/OCF

6.7
Current
36%
Cheaper
vs 3-y average of 10.6

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
6.7
=
Market Cap
$1.5B
/
Operating Cash Flow
$238.5m

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
6.7
=
Market Cap
$1.5B
/
Operating Cash Flow
$238.5m

Valuation Scenarios

Perrigo Company PLC is trading below its 3-year average

If P/OCF returns to its 3-Year Average (10.6), the stock would be worth $18.3 (57% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+292%
Average Upside
119%
Scenario P/OCF Value Implied Price Upside/Downside
Current Multiple 6.7 $11.69
0%
3-Year Average 10.6 $18.3
+57%
5-Year Average 12 $20.71
+77%
Industry Average 26.5 $45.87
+292%
Country Average 10.1 $17.47
+49%

Forward P/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward P/OCF

Peer Comparison

All Multiples
P/OCF
P/E
All Countries
Close
Market Cap P/OCF P/E
IE
Perrigo Company PLC
NYSE:PRGO
1.6B USD 6.7 -1.1
US
Eli Lilly and Co
NYSE:LLY
867B USD 51.6 42
US
Johnson & Johnson
NYSE:JNJ
555.4B USD 22.6 26.4
CH
Roche Holding AG
SIX:ROG
248.4B CHF 13.2 19.3
UK
AstraZeneca PLC
LSE:AZN
224.8B GBP 20.4 29.1
CH
Novartis AG
SIX:NOVN
221.8B CHF 14.6 20
US
Merck & Co Inc
NYSE:MRK
283.6B USD 17.2 15.5
IE
Endo International PLC
LSE:0Y5F
244.4B USD 907.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 9.2 10.7
US
Pfizer Inc
NYSE:PFE
151.6B USD 13 19.5
US
Bristol-Myers Squibb Co
NYSE:BMY
118.8B USD 8.4 16.8
P/E Multiple
Earnings Growth PEG
IE
Perrigo Company PLC
NYSE:PRGO
Average P/E: 22.2
Negative Multiple: -1.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.4
8%
3.3
CH
Roche Holding AG
SIX:ROG
19.3
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
29.1
25%
1.2
CH
Novartis AG
SIX:NOVN
20
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.5
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.7
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.5
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1.1

Market Distribution

In line with most companies in Ireland
Percentile
38th
Based on 248 companies
38th percentile
6.7
Low
0 — 6.1
Typical Range
6.1 — 14.8
High
14.8 —
Distribution Statistics
Ireland
Min 0
30th Percentile 6.1
Median 10.1
70th Percentile 14.8
Max 794.7

Perrigo Company PLC
Glance View

Perrigo Company PLC, a stalwart in the pharmaceutical and healthcare sectors, has carved a niche by specializing in over-the-counter (OTC) health and wellness products. This Dublin-based company traces its origins back to 1887, in Allegan, Michigan, where it began as a modest packager of home remedies. Over the decades, Perrigo has evolved into a global powerhouse that provides affordable and quality healthcare products, distributing them across various markets around the world. Its strategy hinges on delivering effective OTC solutions and a wide array of consumer self-care products, making it a familiar presence in households seeking reliable alternatives to more expensive brand-name pharmaceuticals. Perrigo's business model is centered on offering value to both consumers and retailers. By producing generic versions of well-known drugs, it captures a significant share of the market driven by cost-conscious customers. This approach also involves collaborating with retail giants to supply their private label OTC medications, a mutually beneficial arrangement that allows retailers to offer lower-cost alternatives under their own brands while maintaining healthy margins. Beyond just OTC medications, Perrigo has expanded its offerings to include nutritional products and topical solutions, further diversifying its portfolio and revenue streams. The company's consistent investment in innovation and keen attention to regulatory compliance underscore its commitment to quality and safety, attributes that resonate well in an industry guided by trust and efficacy.

PRGO Intrinsic Value
43.73 USD
Undervaluation 73%
Intrinsic Value
Price $11.69
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett